https://www.selleckchem.com/products/xl092.html
3% (7.6%-98.6%). Evaluation of paired PB and BM samples showed similar proportion of CD26+LSCs (R 0.969). We confirmed that FCM evaluation of CD26 expression in the PB LSCs is a rapid and specific tool for CML diagnosis. Its utility as a marker for residual disease evaluation can also be explored in the future. We confirmed that FCM evaluation of CD26 expression in the PB LSCs is a rapid and specific tool for CML diagnosis. Its utility as a marker for residual disease evaluation can also be explored in the future. Venous thromboembolism (
Me gusta
Comentario
Compartir
